RiNA GmbH Acquires Roche RTS Protein Expression Portfolio
News Sep 09, 2009
Roche and RiNA GmbH of Berlin have agreed to transfer the complete Roche Applied Science RTS Protein Expression portfolio to RiNA GmbH, effective September 15, 2009.
RiNA will contribute its longstanding experience in the field of cell-free expression systems and continue production at the same quality standards defined by Roche. Responsible for sales, support, and distribution of the RTS portfolio worldwide will be 5 PRIME 5 PRIME GmbH of Hamburg, adding an enthusiastic, fast-growing global team of support, direct sales, and distributors. Both partners are committed to maintaining unchanged quality and price of RTS products.
“Roche Applied Science is focusing on innovative technologies in genomics, and we believe that a company specializing in proteomics will be able to develop the potential of RTS technology much faster than we can,” states Manfred Baier, Head of Roche Applied Science.
Leo W. Tristram, CEO of RiNA GmbH says, “The RTS cell-free expression kits ideally complement the RiNA product portfolio and its dedicated customer-specific service for cell-free biosynthesis. Together with 5 PRIME products for purifying and detecting recombinant proteins, RTS technology will form a strong basis for joint development of innovative products in this dynamic field.”
“This agreement allows us to address the attractive market for cell-free protein expression with a well established product line,” states Bernd Haase, CEO of 5 PRIME. “RTS products are renowned for overcoming a key bottleneck in functional proteomics – limited access to pure proteins. The unique technology underlying RTS kits generates high protein yields and will serve as a cornerstone of 5 PRIME’s proteomics line.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.